Did you get your copy of the
FenceBuilder Newsletter?

View the latest Fence Builder Newsletter

View all Past Issues here

Cannabis as Medicine? Overview

It is utterly mind-blowing that people have no idea that Cannabis has been part of the medical prescription landscape for over 20 years. That’s right T. G. A (Therapeutic Goods Administration) trialled and approved cannabis based medicines have been available as an option to alleviate, if only in small ways, some of the symptoms of a couple of diseases or help with recovery from treatment. However, the claims of this plant being a ‘miracle cure’ for just about everything, have existed for of 100 years… yet in no credible and advanced research has any of the properties of the Cannabis plant ‘cured’ anything, ever!

There is no argument that some components of this incredibly complex plant can have some therapeutic benefit, be it ever so small, but deriving such from the plant with out co-opting some of the more detrimental components has proven incredibly difficult. On top of that, the evidence emerging from latest science, sees that some of these therapies, do more harm than good, with the temporary alleviating of a symptom on one hand, and incurring along term genetic harm on the other!

Again if facts and evidence matter to your best-practice health care, then this is the space for you. Make informed decisions based on science, and not quackery!


Liver safety concerns were raised in randomized controlled trials of cannabidiol (CBD) in patients with Lennox‐Gastaut and Dravet syndromes but the relevance of these concerns to healthy adults consuming CBD is unclear. The objective of this manuscript is to report on liver safety findings from healthy adults who received therapeutic daily doses of CBD for ~3.5 weeks and to investigate any correlation between transaminase elevations and baseline characteristics, pharmacogenetic, and pharmacokinetic data. Sixteen healthy adults were enrolled in a phase 1, open‐label, fixed single‐sequence drug‐drug interaction trial to investigate the effect of repeated dose administration of CBD (1500 mg/day) on cytochrome P450 (CYP) 1A2 activity. Seven (44%) participants experienced peak serum alanine aminotransferase (ALT) values greater than the upper limit of normal (ULN). For 5 (31%) participants, the value exceeded 5× ULN, therefore meeting the international consensus criteria for drug‐induced liver injury. There was no correlation between transaminase elevations and baseline characteristics, CYP2C19 genotype, or CBD plasma concentrations. All ALT elevations above the ULN began within 2–4 weeks of initial exposure to CBD. Among the 6 participants with ALT elevations who were discontinued from the protocol, some had symptoms consistent with hepatitis or hypersensitivity.

We conclude that healthy adults consuming CBD may experience elevations in serum ALT consistent with drug‐induced liver injury. Given the demonstrated inter‐individual variation in susceptibility, clinicians should be alert to this potential effect from CBD, which is increasingly available in various non‐prescription forms and doses to consumers.

For complete research

Featured Website

World Federation Against Drugs

World Federation Against Drugs (W.F.A.D) Dalgarno Institute is a member of this global initiative. For evidence based data on best practice drug policy in the global context.
Featured Website
Alt Tag

Institute for Behavior and Health

The Institute for Behavior and Health, Inc. is to reduce the use of illegal drugs. We work to achieve this mission by conducting research, promoting ideas that are affordable and scalable...
Featured Website

Drug Free Australia

Drug Free Australia Website. Drug Free Australia is a peak body, representing organizations and individuals who value the health and wellbeing of our nation...
Featured Website

Drug Advisory Council of Australia (D.A.C.A)

Drug Advisory Council of Australia (D.A.C.A) Dalgarno Institute is an executive member of this peak body. For updates on current illicit drug issues.
Featured Website

International Task Force on Strategic Drug Policy

(I.T.F.S.D.P) This international peak body continues to monitor and influence illicit drug policy on the international stage. Dalgarno Institute is a member organisation.
Featured Website

Smart Approaches to Marijuana

Smart Approaches to Marijuana. SAM's leaders are among the world's most prominent voices calling for science-based marijuana education and awareness.

21 Be There

There isn’t merely data sharing - it isn't about promoting a 'one dimensional' legislative solution to a complex problem
Featured Website

Drug Free Futures

Drug Policy Futures believes in engaging in an open dialogue about the strengths and weaknesses of global drug policies...
Featured Website

Action Alcohol

The National Alliance for Action on Alcohol is a national coalition of health and community organisations from across Australia that has been formed with the goal of reducing alcohol-related harm.
Featured Website

Greater Risk

Greater Risk Website - The younger they start the greater the risk...
Featured Website

Rivermend Health

RiverMend Health is a premier provider of scientifically driven, specialty behavioral health services to those suffering from alcohol and drug dependency, dual disorders, eating disorders, obesity and chronic pain.
Featured Website

Evidence-Based Practices Resource Center

SAMHSA is committed to improving prevention, treatment, and recovery support services for mental and substance use disorders.
Featured Website


SAMHSA is committed to improving prevention, treatment, and recovery support services for mental and substance use disorders.